Affimed (NASDAQ:AFMD – Get Free Report) has been assigned a consensus recommendation of “Buy” from the five ratings firms that are currently covering the stock, MarketBeat.com reports. Five analysts have rated the stock with a buy rating. The average 1 year price objective among analysts that have issued a report on the stock in the last year is $45.00.
AFMD has been the subject of a number of research reports. HC Wainwright lifted their price objective on Affimed to $10.00 and gave the company a “buy” rating in a research note on Monday, April 1st. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Affimed in a research note on Monday, April 1st. StockNews.com initiated coverage on Affimed in a research note on Tuesday, January 2nd. They issued a “sell” rating for the company. Finally, Wells Fargo & Company dropped their price objective on Affimed from $30.00 to $25.00 and set an “overweight” rating for the company in a research note on Monday, April 1st.
Get Our Latest Report on Affimed
Affimed Trading Down 4.5 %
Institutional Inflows and Outflows
Several institutional investors and hedge funds have recently bought and sold shares of the stock. Vestal Point Capital LP acquired a new position in Affimed during the 4th quarter worth $341,000. BNP Paribas Financial Markets grew its stake in Affimed by 39.9% during the 4th quarter. BNP Paribas Financial Markets now owns 571,975 shares of the biopharmaceutical company’s stock worth $357,000 after purchasing an additional 163,162 shares in the last quarter. EWA LLC acquired a new position in shares of Affimed during the 4th quarter worth about $89,000. abrdn plc acquired a new position in shares of Affimed during the 4th quarter worth about $130,000. Finally, Y Intercept Hong Kong Ltd acquired a new position in shares of Affimed during the 2nd quarter worth about $129,000. 30.82% of the stock is owned by institutional investors and hedge funds.
About Affimed
Affimed N.V., a clinical-stage biopharmaceutical company, focuses on discovering and developing cancer immunotherapies in the United States, Germany, and Europe. Its lead product candidates include AFM13 that has completed Phase 2 clinical trial for CD30-positive lymphoma, Phase II clinical trial for hodgkin lymphoma, and completed Phase II clinical study for peripheral T-cell lymphoma; AFM24, a tetravalent, bispecific epidermal growth factor receptor, and CD16A-binding innate cell engager, which is in Phase IIa clinical trial for the treatment of advanced cancers; and AFM28, an innate cell engager (ICE), which is in preclinical development to treat acute myeloid leukemia.
See Also
- Five stocks we like better than Affimed
- Profitably Trade Stocks at 52-Week Highs
- The Charles Schwab Company Can Hit New Highs
- Low PE Growth Stocks: Unlocking Investment Opportunities
- Costco vs. Walmart: Revenue Comparison of Two Retail Giants
- Retail Stocks Investing, Explained
- 3 Energy Plays for Cash Flow: Buy 1 or Buy Them All
Receive News & Ratings for Affimed Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Affimed and related companies with MarketBeat.com's FREE daily email newsletter.